Ildong Pharmaceutical Co., Ltd.
249420.KS
Korea Exchange15,400.00
KRW
+550.00
- -
Ildong Pharmaceutical Co., Ltd.
249420.KS
(Korea Exchange)
Recent
price
15,400.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ildong Pharmaceutical Co., Ltd. develops, manufactures, and markets a broad portfolio of pharmaceutical products, including prescription and over-the-counter drugs, active pharmaceutical ingredients, probiotics, health supplements, medical devices, and cosmetics in South Korea and select international markets. The company offers generic and specialty drugs such as vitamins and nutrients (Aronamin, Biovita), probiotics and anti-diarrheal agents, antibiotics, antifungal and antiviral products, antihistamines, antineoplastic agents (Algik Inj. pemetrexed, Specssa Tab. gefitinib, Xelobig Tab. capecitabine), nonsteroidal anti-inflammatory drugs and analgesics, fixed-dose combinations for cardiovascular conditions (Telostop, Twotops, Droptop), respiratory medications (Cuninta Tab. nintedanib for interstitial lung disease), gastrointestinal treatments including P-CAB peptic ulcer drugs, endocrine and metabolic agents, central nervous system drugs, dermatological and topical preparations (Meditouch wound care dressings), urogenital products, and hyaluronic acid-based fillers; it also provides APIs like fursultiamine HCl, benidipine HCl, topiramate, rivaroxaban, and linagliptin, alongside contract manufacturing services through GMP-certified facilities for antibiotics and oncology drugs. Founded in 1941 and headquartered in Seoul, South Korea, Ildong operates primarily in the healthcare sector with subsidiaries including Ildong Bioscience for probiotics, Ildong Hyaltech for hyaluronic acid, Ildong Healthcare for lifestyle products, and iLeadBMS for novel drug discovery in oncology, autoimmune, and fibrotic diseases; the company exports to approximately 20 countries, with a focus on Southeast Asia, and targets hospitals, clinics, and consumers through distribution channels like Ildong Ecommerce. Recent developments include the acquisition of a 22.5% stake in Ildong Bioscience from Ildong Holdings for KRW 14.2 billion in July 2025 to streamline operations and strengthen its probiotics business; the launch of Cuninta-Nintedanib for interstitial lung disease in April 2025, marked by a symposium with leading respiratory specialists; FDA Orphan Drug Designation for iLeadBMS's IL21120033 CXCR7 agonist targeting idiopathic pulmonary fibrosis in February 2025; participation in CPhI Worldwide 2024 to promote global exports, CMO partnerships, and pipelines like GLP-1 diabetes/obesity drugs (ID110521156), P-CAB (ID120040002), Parkinson's treatments (ID119040338), and MASH candidates (ID119031166); a strategic collaboration with Evotec SE for proprietary project acceleration; and publication of its 2025 Sustainability Report in June 2025 emphasizing ESG advancements in climate response, human resources, and quality management.